Screener
Bruker BRKR Bsi Biospin — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bruker in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Bruker’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:24 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335226
| Line item | Three Months Ended June 30, 2026 / BSI Bio Spin | Three Months Ended June 30, 2026 / BSI CALID | Three Months Ended June 30, 2026 / BSI NANO | Three Months Ended June 30, 2026 / BEST | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / BSI Bio Spin | Three Months Ended June 30, 2025 / BSI CALID | Three Months Ended June 30, 2025 / BSI NANO | Three Months Ended June 30, 2025 / BEST | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Segment expenses: | ||||||||||
| Cost of revenue | $94.1 | $126.1 | $123.7 | $59.8 | $403.7 | $108.1 | $125.6 | $125.6 | $52.3 | $411.6 |
| Selling, general and administrative | 38.4 | 79.3 | 68.6 | 5.8 | 192.1 | 40.9 | 76.9 | 72.7 | 5.7 | 196.2 |
| Research and development | 21.5 | 32.6 | 39.2 | 1.0 | 94.3 | 23.2 | 30.0 | 44.4 | 1.1 | 98.7 |
| Segment operating income | $41.7 | $72.3 | $29.8 | $7.6 | $151.4 | $23.1 | $53.3 | $9.4 | $7.2 | $93.0 |
| Reconciliation of Total operating income: | ||||||||||
| Corporate, elimination and other (a) | $32.8 | $21.1 | ||||||||
| Adjustments and reconciling items (b) | 183.9 | 60.0 |
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Bruker's bsi biospin — research and development expense?
- Bruker (BRKR) reported bsi biospin — research and development expense of $21.5M in Q2 2026.
- How has Bruker's bsi biospin — research and development expense changed year-over-year?
- Bruker's bsi biospin — research and development expense decreased by 7.3% year-over-year, from $23.2M to $21.5M.
- What is the long-term trend for Bruker's bsi biospin — research and development expense?
- Over 3 years (2022 to 2025), Bruker's bsi biospin — research and development expense has grown at a 11.6% compound annual growth rate (CAGR), from $67.4M to $93.7M.
- What does bsi biospin — research and development expense mean?
- This represents the investment made by the BioSpin segment into the discovery, design, and development of new scientific instruments and diagnostic technologies. It is a critical indicator of the segment's commitment to innovation and long-term competitive positioning. Sustained investment is necessary to maintain technological leadership in the life sciences market.
Ask your AI about Bruker's bsi biospin — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude